Printer Friendly
The Free Library
4,292,724 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

High-Level Ciprofloxacin Resistance in Neisseria gonorrhoeae: First Report from Israel.


To the Editor: We report a case of male gonococcal urethritis that persisted despite ciprofloxacin ciprofloxacin /cip·ro·flox·a·cin/ (sip?ro-flok´sah-sin) a synthetic antibacterial effective against many gram-positive and gram-negative bacteria; used as the hydrochloride salt.

cip·ro·flox·a·cin (s
 therapy. The isolate was found to be highly resistant (MIC 32 [micro]g/mL).

A 30-year-old man visited his family physician with a 2-day history of urethral discharge and dysuria
dys·uric (-yrk) adj.
. The symptoms began 7 days after a single, unprotected orogenital contact with a female hitchhiker. The patient denied exchange of money for the act and reported no other recent sex partners or travel outside Israel. After a urethral swab was obtained for culture, the patient received a single dose of ciprofloxacin (500 mg orally). Growth of Neisseria Neisseria /Neis·se·ria/ (ni-ser´e-ah) a genus of gram-negative bacteria (family Neisseriaceae), including N. gonorrhoe´ae, the etiologic agent of gonorrhea, N. meningi´tidis, a prominent cause of meningitis and the specific etiologic agent of meningococcal meningitis. gonorrhoeae was subsequently reported. However, symptoms persisted, and a regimen of doxycycline (100 mg orally twice a day for 10 days) was initiated. After temporary clinical improvement, the patient returned with worsening symptoms: bloody urethral discharge, severe dysuria, edema of the penis, and painful erection. N. gonorrhoeae was reisolated from a repeat urethral swab. When a single dose of ceftriaxone ceftriaxone /cef·tri·ax·one/ (cef?tri-ak´son) a semisynthetic, ß–resistant, third-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria, used as the sodium salt.

cef·tri·ax·one (s
 (250 mg) was administered intramuscularly, clinical cure was prompt.

Susceptibility testing was performed on the second isolate by using the E-test method (AB Biodisk, Solna, Sweden) on a medium containing GC agar base and 1% defined growth supplement. The MIC of ciprofloxacin was 32 [micro]g/mL, penicillin 1.5 [micro]g/mL, tetracycline 2 [micro]g/mL, and ceftriaxone 0.016 [micro]g/mL. The isolate did not produce beta-lactamase. It was classified as a [CMRNG.sup.PT] phenotype (N. gonorrhoeae with chronomosomally mediated resistance to both penicillin and tetracycline).

Gonorrhea was considered a rare disease in Israel in the 1990s: the average annual incidence was 0.89 reported cases per 100,000 population (1). Most laboratories did not carry appropriate media, and susceptibility testing of N. gonorrhoeae was not performed routinely. Quinolones and spectinomycin are the antibiotics most commonly used to treat the infection. Nevertheless, we are not aware of any instance of clinical failure following fluoroquinolone fluoroquinolone /flu·o·ro·quin·o·lone/ (-kwin´o-lon) any of a subgroup of fluorine-substituted quinolones, having a broader spectrum of activity than nalidixic acid.

fluor·o·quin·o·lone (fl
 therapy. More recently, however, the incidence of gonorrhea has been increasing (2). In response, a surveillance program for monitoring antimicrobial resistance in N. gonorrhoeae has been launched.

Fluoroquinolones and cephalosporins became the recommended drugs for treatment of gonococcal infection after penicillin- and tetracycline-resistant N. gonorrhoeae appeared (3). Gonococcal strains with reduced in vitro susceptibility to fluoroquinolones (MIC, 0.125 [micro]g/mL to 0.5 [micro]g/mL) were first described in the mid-1980s (4) and are now occurring worldwide (5).

Fluoroquinolone-resistant N. gonorrhoeae (ciprofloxacin MIC [is greater than] 1.0 [micro]g/mL) emerged during the 1990s and became well established in several Asian countries (6). In Japan, the rate of ciprofloxacin resistance increased from 6.6% in 1993-1994 to 24.4% in 1997-1998 (7). More recently, high-level resistance to ciprofloxacin and reports of treatment failure have appeared (8). Strains with ciprofloxacin MICs of [is greater than or equal to] 8.0 [micro]g/mL were first isolated in 1994 (6) and are detected mostly in the Far East. Two cases of gonococcal infection by strains with an MIC of 16 [micro]g/mL were recently reported in the United States (9). Gonococcal resistance to fluoroquinolones is associated with mutations in the genes encoding DNA gyrase DNA gyrase (ji´ras) a type II DNA topoisomerase. (gyrA) and topoisomerase (parC) as well as change in porin permeability and reduced intracellular drug accumulation (6). In view of the increasing resistance to fluoroquinolones, ceftriaxone, cefixime cefixime /ce·fix·ime/ (se-fik´sem) a third-generation cephalosporin effective against a wide range of bacteria, used in the treatment of otitis media, bronchitis, pharyngitis, tonsillitis, gonorrhea, and urinary tract infections., or spectinomycin is now recommended if an infection was acquired in Asia or other areas with known fluoroquinolone resistance (9).

Our patient reported no travel to the Far East, and his sex partner, who could not be located for follow-up, was not Asian; her travel history was unknown. The mode of transmission of this infection was fellatio fellatio /fel·la·tio/ (fe-la´she-o) oral stimulation or manipulation of the penis.

fel·la·ti·o (f-l
. Condoms are often not used in this form of intercourse, even by those who regularly use condoms for genito-genital sex, because of the mistaken belief that infection is not spread through this form of intercourse. It is now well established that oral sex plays an important role in HIV transmission (10), and condoms should be used with any form of intimate sexual contact.

Michael Dan,(*) Francesca Poch,(*) Daniel Shpitz,([dagger]) and Bracha Sheinberg([dagger])

(*) Infectious Disease Unit, E. Wolfson Hospital, Holon Holon (hōlôn`), city (1994 pop. 163,700), W central Israel. Manufactures include textiles, metal and leather goods, processed foods, furniture, glassware, plastics, and construction materials. Holon was founded in 1940 with the merger of several residential neighborhoods., Israel, and ([dagger]) Maccabi Health Services, Rishon-le-Zion, Israel

References

(1.) The Israel Center for Diseases Control. Notifiable infectious disease in Israel, 1951-1995. Israel: State of Israel: Ministry of Health; 1996. pub. no. 201.

(2.) District Health Office, Tel-Aviv. Report on emerging issues, July-December 1999. State of Israel: Ministry of Health; Jan 10, 2000.

(3.) Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. Mor Mortal Wkly Rep 1998;47(RR-1):1-116.

(4.) Tapsall JW, Shultz TR, Phillips EA. Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to quinolone antibiotics. Pathology 1992;24:27-31.

(5.) Quinn TC. The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect Dis Clin North Am 1997;11:884-904.

(6.) Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997;3:33-8.

(7.) Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol 2000;38:521-5.

(8.) Tapsall JW, Limnios EA, Thacker C, Donovan B, Lynch SD, Kirky LJ, et al. High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sex Transm Dis 1995;22:310-11.

(9.) Centers for Disease Control and Prevention. Fluoroquinolone-resistant Neisseria gonorrhoeae--San Diego, California, 1997. Mor Mortal Wkly Rep 1998;47:405-8.

(10.) Dillon B, Hecht FM, Swanson M, Goupil-Sormany I, Grant RH, Chesney MA, et al. Primary HIV infections associated with oral transmission. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Jan 30-Feb 2, 2000 (Abstract 473).
COPYRIGHT 2001 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Sheinberg, Bracha
Publication:Emerging Infectious Diseases
Geographic Code:7ISRA
Date:Jan 1, 2001
Words:962
Previous Article:Strengthening National Preparedness for Smallpox: An Update.
Next Article:An Unusual Bacterium Causing a Brain Abscess.(Brief Article)
Topics:



Related Articles
Belligerent bugs make Korean debut. (antibiotic resistance of gonorrhea microbe)
Bacterial Resistance to Antimicrobial Agents: Selected Problems in France, 1996 to 1998.
First Glycopeptide-Resistant Enterococcus faecium Isolate from Blood Culture in Ankara, Turkey.(Brief Article)
Lack of Evidence for Chloramphenicol Resistance in Neisseria meningitidis, Africa.
Decreased Susceptibility to Ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom.
Enteric Fever Treatment Failures: A Global Concern.
Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. (Research).
Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel...
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.(Dispatches)
Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae Clones, Spain.(Research)

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles